Agios Pharmaceuticals Inc (AGIO)’s Stock Formed A Several Months Bullish Wedge Up Chart Pattern

September 17, 2017 - By Peter Erickson

Investors sentiment decreased to 1.1 in 2016 Q4. Its down 0.62, from 1.72 in 2016Q3. It dived, as 23 investors sold Agios Pharmaceuticals Inc shares while 45 reduced holdings. 19 funds opened positions while 56 raised stakes. 37.23 million shares or 3.48% more from 35.97 million shares in 2016Q3 were reported.
Us National Bank De has invested 0% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO). California State Teachers Retirement Systems accumulated 64,341 shares. Blackrock Fund Advsrs holds 0.01% or 917,140 shares. Oxford Asset Mngmt has 0.08% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 40,276 shares. Financial Bank Of Montreal Can reported 1,852 shares stake. Marshall Wace Ltd Liability Partnership invested in 0.01% or 30,528 shares. Pub Employees Retirement Association Of Colorado reported 6,194 shares. Quantbot Technology L P stated it has 1,875 shares. Northern Tru owns 158,497 shares for 0% of their portfolio. Spark Mgmt Ltd Liability has 50,000 shares. Arrowpoint Asset Mngmt Limited Company holds 0.04% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 63,507 shares. Janus Mngmt Limited Liability has 0.01% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO). California-based Wells Fargo & Co Mn has invested 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Td Asset Inc holds 25,300 shares or 0% of its portfolio. First Trust Advsr L P accumulated 542,867 shares.

Since March 20, 2017, it had 0 insider buys, and 7 insider sales for $906,379 activity. $108,132 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) was sold by Cantley Lewis Clayton Jr. on Wednesday, March 22. The insider Schenkein David P sold $150,180. Biller Scott also sold $354,090 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares.

The stock of Agios Pharmaceuticals Inc (AGIO) formed an up wedge with $71.74 target or 8.00 % above today’s $66.43 share price. The 5 months wedge indicates low risk for the $3.21B company. If the $71.74 price target is reached, the company will be worth $256.80 million more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock increased 1.28% or $0.84 on September 15, reaching $66.43. About 863,491 shares traded or 99.81% up from the average. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 8.52% since September 17, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.

Analysts expect Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report $-1.74 EPS on November, 2.They anticipate $0.11 EPS change or 6.75 % from last quarter’s $-1.63 EPS. After having $-1.78 EPS previously, Agios Pharmaceuticals Inc’s analysts see -2.25 % EPS growth.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage

Among 15 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 11 have Buy rating, 0 Sell and 4 Hold. Therefore 73% are positive. Agios Pharmaceuticals had 35 analyst reports since July 23, 2015 according to SRatingsIntel. Canaccord Genuity maintained it with “Hold” rating and $93 target in Friday, August 7 report. The firm earned “Neutral” rating on Friday, August 19 by BTIG Research. On Monday, June 26 the stock rating was downgraded by Janney Capital to “Neutral”. Cowen & Co maintained the stock with “Buy” rating in Tuesday, August 1 report. JP Morgan upgraded the shares of AGIO in report on Monday, June 13 to “Overweight” rating. The company was maintained on Monday, November 9 by Roth Capital. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) earned “Buy” rating by Canaccord Genuity on Monday, June 5. Needham initiated the stock with “Buy” rating in Monday, October 24 report. The firm earned “Outperform” rating on Thursday, July 23 by Northland Capital. Canaccord Genuity upgraded it to “Buy” rating and $90 target in Monday, June 13 report.

More news for Agios Pharmaceuticals Inc (NASDAQ:AGIO) were recently published by: Seekingalpha.com, which released: “Agios, Amigos!” on May 26, 2017. Seekingalpha.com‘s article titled: “Agios: Smooth First Mover In Cancer Metabolism” and published on August 08, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.